Serum levels of cartilage oligomeric matrix protein are elevated in rheumatoid arthritis, but not in inflammatory rheumatic diseases such as psoriatic arthritis, reactive arthritis, Raynaud's syndrome, scleroderma, systemic lupus erythematosus, vasculitis and Sjögren's syndrome by Skoumal, Martin et al.
73
CRP = C-reactive protein; ELISA = enzyme-linked immunosorbent assay; NF = nuclear factor; PsA = psoriatic arthritis; RA = rheumatoid arthritis;
sCOMP = cartilage oligomeric matrix protein in serum.
Available online http://arthritis-research.com/content/6/2/73
Progressive bone and cartilage destruction in arthritic
joints leads to irreversible joint destruction and, sub-
sequently, to functional declines and to work disability.
During recent years a lot of interest has been focused on
serum biomarkers in the clinic to evaluate the ongoing
disease process in the cartilage and bone. New
biomarkers such as osteoprotegerin or receptor activator
of NF-κB ligand have been developed to describe the
local bone process in affected joints.
Cartilage oligomeric matrix protein in serum (sCOMP) is a
biomarker for the cartilage turnover [1] and is elevated in
patients with rheumatoid arthritis (RA), in patients with
osteoarthritis and in patients with articular trauma.
sCOMP is a valuable parameter for the assessment of
therapy response in RA [2]. Elevated serum levels of
sCOMP showed a significant correlation with the
progression of the Larsen score within 5 years in a patient
group with established RA, and sCOMP is also described
as a prognostic factor in early RA [3,4]. Inflammatory
synovium has been considered a potential tissue source of
sCOMP since the molecule has been detected in the
synovium in both RA [5,6] and osteoarthritis [6]. However,
less is known of how much sCOMP the synovium
produces in other inflammatory rheumatic diseases.
The aim of our study was to investigate whether increased
sCOMP is a specific marker for joint destruction,
comparing sCOMP between patients with RA and
patients with other inflammatory rheumatic diseases with
less cartilage-destructive arthritis.
Levels of sCOMP and serum C-reactive protein (CRP)
were measured in 150 patients. Seventy-seven of the
patients had seropositive erosive RA, fifteen patients had
psoriatic arthritis (PsA), ten patients had reactive arthritis,
twelve patients had primary Raynaud’s syndrome, eleven
patients had scleroderma, nine patients had systemic lupus
erythematosus, seven patients had leucozytoclastic
vasculitis, five patients had primary Sjögren’s syndrome
and four patients had CRST (calcinosis, Raynaud’s
syndrome, scleroderma, teleangiectasia) syndrome and
primary biliary cirrhosis. Cartilage oligomeric matrix protein
was measured with an ELISA according to the recommen-
dation of the manufacturer (cut-off point, 10 U/l; AnaMar
Medical AB, Uppsala, Sweden). Statistical evaluation was
calculated by paired t test.
Elevated sCOMP levels were detected only in patients
with RA and with PsA. We found a significant difference
between sCOMP in patients with RA and PsA (P = 0.01),
in patients with reactive arthritis (P = 0.0001), in patients
with Raynaud’s syndrome (P = 0.0005), in patients with
scleroderma (P = 0.003), in patients with systemic lupus
erythematosus (P = 0.0002), in patients with leucozyto-
clastic vasculitis (P= 0.0004) and in patients with Sjögren’s
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syndrome (P = 0.0007), but not in patients with CRST
syndrome and primary biliary cirrhosis (P = 0.06) (Fig. 1).
sCOMP did not differ significantly between Steinbrocker
stages II–IV in RA patients. Levels of sCOMP were not
significantly associated with CRP (P = 0.78).
Cartilage oligomeric matrix protein is described as an
indicator for the current extent of cartilage destruction in
RA. In our patient group elevated levels of sCOMP could
only be detected in patients with RA and in a few patients
with PsA, but not in patients with reactive arthritis, with
Raynaud’s syndrome, with scleroderma, with systemic
lupus erythematosus, with leucozytoclastic vasculitis or
with Sjögren’s syndrome. This result indicates that among
these inflammatory arthritic diseases cartilage is affected
only in RA. In none of the diseases was sCOMP
associated with inflammation markers such as CRP. This
is not in agreement with other studies where elevated
cartilage oligomeric matrix protein levels were found even
in patients with low clinical prognostic factors (erythrocyte
sedimentation rate, CRP, rheumatoid factor, disease
activity score). However, a correlation between sCOMP
and the delta Larsen score over 5 years in this patient
group could be demonstrated.
Our results further confirm the conclusion that sCOMP
levels are highly specific markers for the cartilage
degradation process in RA [6,7] and are not related to a
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Figure 1
Serum levels of cartilage oligomeric matrix protein (COMP) in
rheumatoid arthritis (RA) and other inflammatory rheumatic diseases.
PsA, psoriatic arthritis; ReA, reactive arthritis; RS, Raynaud’s
syndrome; SCL, scleroderma; SLE, systemic lupus erythematosus; VA,
leucozytoclastic vasculitis; SS, Sjögren’s syndrome; CRST&PBC,
CRST syndrome and primary biliary cirrhosis.
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